首页 > 最新文献

Neuropsychopharmacology Reports最新文献

英文 中文
Factor structure and psychometric properties of the Jordanian version of the depression anxiety stress scale (DASS-21). 约旦版抑郁焦虑压力量表(DASS-21)的因子结构和心理测量特性。
IF 2.5 Q2 Psychology Pub Date : 2024-04-08 DOI: 10.1002/npr2.12442
Khaled A. Al-Dassean, Odeh S. Murad
AIMEarly diagnosis of health conditions such as depression, anxiety, and stress, which have been recognized as global health issues, is essential for providing psychological support to people who experience negative emotions. Therefore, it is important to identify a reliable method for diagnosing depression, anxiety, and stress. To this end, this study investigated the factor structure and evaluated the psychometric properties of the Depression Anxiety Stress Scale-21 (DASS-21) in Jordan.METHODSA university sample of 336 Jordanians completed the Arabic version of the DASS-21 and several psychopathology measures. Cross-sectional study and confirmatory factor analysis (CFA) were applied to achieve the study's aims.RESULTSCFA favored the bifactor model compared to the other four models. In contrast, the Beck Anxiety Inventory (BAI) and the Beck Depression Inventory-II (BDI-II) strongly correlated with the DASS-21, indicating that the DASS-21 has adequate convergent and divergent validity. Subsequently, the scale's discriminant validity was tested using the heterotrait-monotrait (HTMT) correlation ratio, which was found to be relatively insufficient. While DASS-21 showed strong reliability, Cronbach's α and McDonald's omega values ranged between 0.83 and 0.93.CONCLUSIONThe bifactor model best fits the Jordanian sample data. The DASS-21 has optimum psychometric properties; therefore, it can be used to assess the general distress experienced by the Jordanian community during research investigations and in non-clinical settings.
摘要:抑郁、焦虑和压力等健康问题已被公认为全球性健康问题,对它们的早期诊断对于为出现负面情绪的人提供心理支持至关重要。因此,确定一种诊断抑郁、焦虑和压力的可靠方法非常重要。为此,本研究在约旦调查了抑郁焦虑压力量表-21(DASS-21)的因子结构,并评估了其心理测量特性。结果与其他四个模型相比,双因素模型更受青睐。相比之下,贝克焦虑量表(BAI)和贝克抑郁量表-II(BDI-II)与 DASS-21 具有很强的相关性,这表明 DASS-21 具有充分的收敛效度和发散效度。随后,我们使用异质-单质(HTMT)相关比对量表的判别效度进行了检验,结果发现该量表的判别效度相对不足。DASS-21 显示出很强的信度,Cronbach's α 和 McDonald's ω 值介于 0.83 和 0.93 之间。DASS-21 具有最佳的心理测量特性;因此,它可用于评估约旦社区在研究调查和非临床环境中经历的一般困扰。
{"title":"Factor structure and psychometric properties of the Jordanian version of the depression anxiety stress scale (DASS-21).","authors":"Khaled A. Al-Dassean, Odeh S. Murad","doi":"10.1002/npr2.12442","DOIUrl":"https://doi.org/10.1002/npr2.12442","url":null,"abstract":"AIM\u0000Early diagnosis of health conditions such as depression, anxiety, and stress, which have been recognized as global health issues, is essential for providing psychological support to people who experience negative emotions. Therefore, it is important to identify a reliable method for diagnosing depression, anxiety, and stress. To this end, this study investigated the factor structure and evaluated the psychometric properties of the Depression Anxiety Stress Scale-21 (DASS-21) in Jordan.\u0000\u0000\u0000METHODS\u0000A university sample of 336 Jordanians completed the Arabic version of the DASS-21 and several psychopathology measures. Cross-sectional study and confirmatory factor analysis (CFA) were applied to achieve the study's aims.\u0000\u0000\u0000RESULTS\u0000CFA favored the bifactor model compared to the other four models. In contrast, the Beck Anxiety Inventory (BAI) and the Beck Depression Inventory-II (BDI-II) strongly correlated with the DASS-21, indicating that the DASS-21 has adequate convergent and divergent validity. Subsequently, the scale's discriminant validity was tested using the heterotrait-monotrait (HTMT) correlation ratio, which was found to be relatively insufficient. While DASS-21 showed strong reliability, Cronbach's α and McDonald's omega values ranged between 0.83 and 0.93.\u0000\u0000\u0000CONCLUSION\u0000The bifactor model best fits the Jordanian sample data. The DASS-21 has optimum psychometric properties; therefore, it can be used to assess the general distress experienced by the Jordanian community during research investigations and in non-clinical settings.","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140728843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vortioxetine-induced syndrome of inappropriate secretion of antidiuretic hormone: A case report. 伏替西汀诱发的抗利尿激素分泌不当综合征:病例报告。
IF 2.5 Q2 Psychology Pub Date : 2024-04-08 DOI: 10.1002/npr2.12438
Taro Sasaki, Yunosuke Shindo, Kota Kikuchi, Yasushi Kawamata, Norio Sugawara, N. Yasui‐Furukori
BACKGROUNDVortioxetine, known for its efficacy in treating depression through its effects on various neurotransmitters, has not been previously reported to induce syndrome of inappropriate secretion of antidiuretic hormone (SIADH).CASE PRESENTATIONThis case report describes a 74-year-old man with major depressive disorder who developed SIADH 1 week after starting treatment with vortioxetine. SIADH is characterized by symptoms such as headache, nausea, disorientation, and seizures, stemming from hyponatremia (123 mEq/L), without dehydration or edema. Vortioxetine was discontinued, and an alternative drug, mianserin, was initiated. The patient was restricted from drinking water due to hyponatremia. The serum Na concentration improved over time to within the normal range by the second week after admission.CONCLUSIONThis is the first case report of vortioxetine-induced SIADH.
背景沃替西汀因其对多种神经递质的影响而具有治疗抑郁症的疗效,但以前从未有报道称其会诱发抗利尿激素不适当分泌综合征(SIADH)。本病例报告描述了一名患有重度抑郁症的 74 岁男性在开始使用沃替西汀治疗一周后出现 SIADH。SIADH 的特征是低钠血症(123 mEq/L)引起的头痛、恶心、定向障碍和癫痫发作等症状,但没有脱水或水肿。患者停用了伏替西汀,并开始服用替代药物米安色林。由于出现低钠血症,患者被限制饮水。随着时间的推移,入院后第二周血清钠浓度有所改善,达到正常范围。
{"title":"Vortioxetine-induced syndrome of inappropriate secretion of antidiuretic hormone: A case report.","authors":"Taro Sasaki, Yunosuke Shindo, Kota Kikuchi, Yasushi Kawamata, Norio Sugawara, N. Yasui‐Furukori","doi":"10.1002/npr2.12438","DOIUrl":"https://doi.org/10.1002/npr2.12438","url":null,"abstract":"BACKGROUND\u0000Vortioxetine, known for its efficacy in treating depression through its effects on various neurotransmitters, has not been previously reported to induce syndrome of inappropriate secretion of antidiuretic hormone (SIADH).\u0000\u0000\u0000CASE PRESENTATION\u0000This case report describes a 74-year-old man with major depressive disorder who developed SIADH 1 week after starting treatment with vortioxetine. SIADH is characterized by symptoms such as headache, nausea, disorientation, and seizures, stemming from hyponatremia (123 mEq/L), without dehydration or edema. Vortioxetine was discontinued, and an alternative drug, mianserin, was initiated. The patient was restricted from drinking water due to hyponatremia. The serum Na concentration improved over time to within the normal range by the second week after admission.\u0000\u0000\u0000CONCLUSION\u0000This is the first case report of vortioxetine-induced SIADH.","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140728223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quantification of cytosine modifications in the aged mouse brain. 衰老小鼠脑内胞嘧啶修饰的定量分析。
IF 2.5 Q2 Psychology Pub Date : 2024-03-01 Epub Date: 2023-12-06 DOI: 10.1002/npr2.12396
Hiroko Sugawara, Akitoshi Date, Satoshi Fuke, Yutaka Nakachi, Tadafumi Kato, Minoru Narita, Miki Bundo, Kazuya Iwamoto

Quantifying cytosine modifications in various brain regions provides important insights into the gene expression regulation and pathophysiology of neuropsychiatric disorders. In this study, we quantified 5-methylcytosine (5-mC), 5-hydroxymethylation (5-hmC), and 5-formylcytosine (5-fC) levels in five brain regions (the frontal lobe, cerebral cortical region without frontal lobe, hippocampus, basal ganglia, and the cerebellum) and the heart at three developmental periods (12, 48, and 101 weeks). We observed significant regional variations in cytosine modification. Notably, regional variations were generally maintained throughout development, suggesting that epigenetic regulation is unique to each brain region and remains relatively stable with age. The 5-mC and 5-hmC levels were positively correlated, although the extent of the correlations seemed to differ in different brain regions. On the contrary, 5-fC levels did not correlate with 5-mC or 5-hmC levels. Additionally, we observed an age-dependent decrease in 5-fC levels in the basal ganglia, suggesting a unique epigenetic regulation mechanism. Further high-resolution studies using animal models of neuropsychiatric disorders as well as postmortem brain evaluation are warranted.

定量分析不同脑区的胞嘧啶修饰为神经精神疾病的基因表达调控和病理生理学提供了重要的见解。在这项研究中,我们量化了5-甲基胞嘧啶(5-mC)、5-羟甲基化(5-hmC)和5-甲酰基胞嘧啶(5-fC)在三个发育时期(12周、48周和101周)的大脑5个区域(额叶、不含额叶的大脑皮质区、海马、基底节和小脑)和心脏中的水平。我们观察到胞嘧啶修饰的显著区域差异。值得注意的是,区域差异在整个发育过程中普遍保持,这表明表观遗传调控对每个大脑区域都是独特的,并且随着年龄的增长保持相对稳定。5-mC和5-hmC水平是正相关的,尽管在不同的大脑区域,相关性的程度似乎有所不同。相反,5-fC水平与5-mC或5-hmC水平无关。此外,我们观察到基底节区5-fC水平的年龄依赖性下降,这表明一种独特的表观遗传调控机制。进一步的高分辨率研究使用动物神经精神疾病模型以及死后大脑评估是有必要的。
{"title":"Quantification of cytosine modifications in the aged mouse brain.","authors":"Hiroko Sugawara, Akitoshi Date, Satoshi Fuke, Yutaka Nakachi, Tadafumi Kato, Minoru Narita, Miki Bundo, Kazuya Iwamoto","doi":"10.1002/npr2.12396","DOIUrl":"10.1002/npr2.12396","url":null,"abstract":"<p><p>Quantifying cytosine modifications in various brain regions provides important insights into the gene expression regulation and pathophysiology of neuropsychiatric disorders. In this study, we quantified 5-methylcytosine (5-mC), 5-hydroxymethylation (5-hmC), and 5-formylcytosine (5-fC) levels in five brain regions (the frontal lobe, cerebral cortical region without frontal lobe, hippocampus, basal ganglia, and the cerebellum) and the heart at three developmental periods (12, 48, and 101 weeks). We observed significant regional variations in cytosine modification. Notably, regional variations were generally maintained throughout development, suggesting that epigenetic regulation is unique to each brain region and remains relatively stable with age. The 5-mC and 5-hmC levels were positively correlated, although the extent of the correlations seemed to differ in different brain regions. On the contrary, 5-fC levels did not correlate with 5-mC or 5-hmC levels. Additionally, we observed an age-dependent decrease in 5-fC levels in the basal ganglia, suggesting a unique epigenetic regulation mechanism. Further high-resolution studies using animal models of neuropsychiatric disorders as well as postmortem brain evaluation are warranted.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10932792/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138499005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A multicenter, single-arm, open-label interventional study of adherence to brexpiprazole during switching from previous antipsychotic drugs in patients with schizophrenia or schizoaffective disorder. 一项多中心、单臂、开放标签的干预性研究,旨在了解精神分裂症或情感分裂症患者从既往的抗精神病药物转用布来匹唑期间的依从性。
IF 2.5 Q2 Psychology Pub Date : 2024-03-01 Epub Date: 2024-01-22 DOI: 10.1002/npr2.12416
Kazuyuki Nakagome, Hisateru Tachimori, Shiro Endo, Ken Murakami, Takaharu Azekawa, Seiji Hongo, Kazunari Niidome, Yoshitsugu Kojima, Sakiko Yamada, Hideki Oi, Tomiki Sumiyoshi

The rate of medication persistence was examined in patients with schizophrenia or schizoaffective disorder during switching from previously administered antipsychotics to brexpiprazole, a new dopamine D2 receptor partial agonist. A multicenter, single-arm, open-label 24-week interventional study was conducted, consisting of two 12-week consecutive periods: an initial switch (by plateau cross-titration) with the subsequent period, followed by a second maintenance period. Prior antipsychotics were olanzapine or risperidone/paliperidone. The primary and secondary outcome measures were medication persistence rates after the first 12 weeks and changes from baseline in the Specific Levels of Functioning Scale (SLOF), Subjective Well-being under Neuroleptic drug treatment Short form (SWNS), and Positive and Negative Syndrome Scale (PANSS) scores, respectively. In total, 79 patients were administered brexpiprazole and the medication persistence rate at 12 weeks was 78.5%, which was significantly higher than the predefined threshold of 65%. Regarding the prior medication, the persistence rate at 12 weeks was 84.6% for olanzapine and 72.5% for risperidone/paliperidone. Significant improvements from baseline were observed in the SLOF, SWNS, and PANSS scores. There were no adverse events of concern. Thus, brexpiprazole appeared to be a suitable antipsychotic on switching from olanzapine, risperidone, or paliperidone.

研究人员考察了精神分裂症或分裂情感障碍患者从之前服用的抗精神病药物转为服用新型多巴胺D2受体部分激动剂布来匹唑期间的药物持续服用率。该研究是一项多中心、单臂、开放标签、为期 24 周的干预性研究,包括两个连续 12 周的阶段:初始转换阶段(通过高原交叉滴定)和随后的阶段,然后是第二个维持阶段。之前的抗精神病药物为奥氮平或利培酮/帕利哌酮。主要和次要结局测量指标分别是头12周后的用药坚持率,以及特定功能水平量表(SLOF)、神经安定药物治疗下的主观幸福感简表(SWNS)和阳性与阴性综合征量表(PANSS)评分与基线相比的变化。共有79名患者接受了布来哌唑治疗,12周后的用药持续率为78.5%,明显高于65%的预设阈值。至于之前服用的药物,奥氮平和利培酮/帕利哌酮的12周持续服药率分别为84.6%和72.5%。与基线相比,SLOF、SWNS和PANSS评分均有显著改善。没有出现令人担忧的不良事件。因此,在从奥氮平、利培酮或帕利哌酮换药时,布来哌唑似乎是一种合适的抗精神病药物。
{"title":"A multicenter, single-arm, open-label interventional study of adherence to brexpiprazole during switching from previous antipsychotic drugs in patients with schizophrenia or schizoaffective disorder.","authors":"Kazuyuki Nakagome, Hisateru Tachimori, Shiro Endo, Ken Murakami, Takaharu Azekawa, Seiji Hongo, Kazunari Niidome, Yoshitsugu Kojima, Sakiko Yamada, Hideki Oi, Tomiki Sumiyoshi","doi":"10.1002/npr2.12416","DOIUrl":"10.1002/npr2.12416","url":null,"abstract":"<p><p>The rate of medication persistence was examined in patients with schizophrenia or schizoaffective disorder during switching from previously administered antipsychotics to brexpiprazole, a new dopamine D<sub>2</sub> receptor partial agonist. A multicenter, single-arm, open-label 24-week interventional study was conducted, consisting of two 12-week consecutive periods: an initial switch (by plateau cross-titration) with the subsequent period, followed by a second maintenance period. Prior antipsychotics were olanzapine or risperidone/paliperidone. The primary and secondary outcome measures were medication persistence rates after the first 12 weeks and changes from baseline in the Specific Levels of Functioning Scale (SLOF), Subjective Well-being under Neuroleptic drug treatment Short form (SWNS), and Positive and Negative Syndrome Scale (PANSS) scores, respectively. In total, 79 patients were administered brexpiprazole and the medication persistence rate at 12 weeks was 78.5%, which was significantly higher than the predefined threshold of 65%. Regarding the prior medication, the persistence rate at 12 weeks was 84.6% for olanzapine and 72.5% for risperidone/paliperidone. Significant improvements from baseline were observed in the SLOF, SWNS, and PANSS scores. There were no adverse events of concern. Thus, brexpiprazole appeared to be a suitable antipsychotic on switching from olanzapine, risperidone, or paliperidone.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10932803/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139521685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-acting injectable antipsychotics as maintenance therapy for schizophrenia during the COVID-19 pandemic: A micro-narrative review. 在 COVID-19 大流行期间,长效注射用抗精神病药物作为精神分裂症的维持疗法:微观叙事回顾。
IF 2.5 Q2 Psychology Pub Date : 2024-03-01 Epub Date: 2024-01-06 DOI: 10.1002/npr2.12413
Yoshiyo Oguchi, Nobumi Miyake, Kumiko Ando

The coronavirus disease pandemic has presented healthcare systems with unprecedented challenges globally and substantially impacted the management of chronic diseases such as schizophrenia. This narrative review highlights the usefulness of long-acting injectable antipsychotics (LAIs) as maintenance therapy for patients with schizophrenia during the pandemic. The analysis of relevant literature and psychiatric survey data revealed diverse trends in LAIs prescription and patient adherence with oral antipsychotics. Although some studies have reported a decrease in LAIs prescriptions owing to pandemic-related disruptions, others have suggested stable patient adherence with oral antipsychotics. Approximately 70% of Japanese psychiatrists reported an increase in schizophrenia relapse rates in a survey, underscoring the critical role of LAIs in maintaining therapeutic stability. The potential benefits of LAIs with extended dosing intervals have been highlighted, including improving oral medication adherence and reducing the frequency of hospital visits. In conclusion, this review emphasizes the continued need for uninterrupted LAIs therapy in conjunction with community and home-based care despite the disruptions caused by the coronavirus disease pandemic. Further development of LAIs maintenance therapy strategies considering the ongoing pandemic and potential future public health emergencies are required.

冠状病毒疾病大流行给全球医疗系统带来了前所未有的挑战,并对精神分裂症等慢性疾病的治疗产生了重大影响。这篇叙述性综述强调了长效注射用抗精神病药物(LAIs)在大流行期间作为精神分裂症患者维持疗法的作用。对相关文献和精神病学调查数据的分析表明,LAIs 处方和患者坚持口服抗精神病药物的趋势各不相同。尽管一些研究报告称,由于大流行造成的干扰,LAIs 的处方量有所减少,但其他研究则表明,患者对口服抗精神病药物的依从性保持稳定。在一项调查中,约 70% 的日本精神科医生表示精神分裂症的复发率有所上升,这凸显了 LAIs 在维持治疗稳定性方面的关键作用。延长给药间隔的 LAIs 的潜在益处也得到了强调,包括改善口服药物的依从性和减少医院就诊频率。总之,本综述强调,尽管冠状病毒疾病大流行造成了混乱,但仍然需要不间断的LAIs治疗,并与社区和家庭护理相结合。考虑到目前的大流行和未来可能发生的公共卫生突发事件,需要进一步制定LAIs维持治疗策略。
{"title":"Long-acting injectable antipsychotics as maintenance therapy for schizophrenia during the COVID-19 pandemic: A micro-narrative review.","authors":"Yoshiyo Oguchi, Nobumi Miyake, Kumiko Ando","doi":"10.1002/npr2.12413","DOIUrl":"10.1002/npr2.12413","url":null,"abstract":"<p><p>The coronavirus disease pandemic has presented healthcare systems with unprecedented challenges globally and substantially impacted the management of chronic diseases such as schizophrenia. This narrative review highlights the usefulness of long-acting injectable antipsychotics (LAIs) as maintenance therapy for patients with schizophrenia during the pandemic. The analysis of relevant literature and psychiatric survey data revealed diverse trends in LAIs prescription and patient adherence with oral antipsychotics. Although some studies have reported a decrease in LAIs prescriptions owing to pandemic-related disruptions, others have suggested stable patient adherence with oral antipsychotics. Approximately 70% of Japanese psychiatrists reported an increase in schizophrenia relapse rates in a survey, underscoring the critical role of LAIs in maintaining therapeutic stability. The potential benefits of LAIs with extended dosing intervals have been highlighted, including improving oral medication adherence and reducing the frequency of hospital visits. In conclusion, this review emphasizes the continued need for uninterrupted LAIs therapy in conjunction with community and home-based care despite the disruptions caused by the coronavirus disease pandemic. Further development of LAIs maintenance therapy strategies considering the ongoing pandemic and potential future public health emergencies are required.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10932768/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139111110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Practical clinical guidelines and pharmacological treatment for attention-deficit hyperactivity disorder in Asia. 亚洲注意缺陷多动障碍的实用临床指南和药物治疗。
IF 2.5 Q2 Psychology Pub Date : 2024-03-01 Epub Date: 2023-12-07 DOI: 10.1002/npr2.12381
Kentaro Kawabe, Fumie Horiuchi, Yu Matsumoto, Saori Inoue, Maya Okazawa, Rie Hosokawa, Kiwamu Nakachi, Junya Soga, Shu-Ichi Ueno

Attention-deficit hyperactivity disorder (ADHD) is characterized by persistent symptoms of inattention, hyperactivity, and impulsivity. Both, stimulant and nonstimulant medications have been approved for the treatment of this disorder. Several Western guidelines recommend the use of prescribed Food and Drug Administration (FDA)-approved medications for ADHD along with parental training in behavior management and behavioral classroom intervention. In 2022, new Japanese guidelines for ADHD were issued, which recommended school environment management and psychosocial treatment as the first-line treatment, with pharmacological treatment added as the second-line treatment. Although Japanese guidelines, including pharmacological treatments, have been established, the guidelines and utilization of ADHD medications across Asian regions are unclear. Therefore, to appropriately evaluate the strategy of pharmacological treatments for ADHD, we investigated Asian regional guidelines for ADHD medication in children. We also reviewed the guidelines in Malaysia, Singapore, India, and the Republic of Korea and found that these guidelines differ from Western guidelines.

注意缺陷多动障碍(ADHD)的特征是持续的注意力不集中、多动和冲动。兴奋剂和非兴奋剂药物都已被批准用于治疗这种疾病。一些西方的指导方针建议使用美国食品和药物管理局(FDA)批准的治疗多动症的药物,同时对父母进行行为管理和行为课堂干预方面的培训。2022年,日本发布了新的ADHD指南,建议将学校环境管理和社会心理治疗作为一线治疗,并增加药物治疗作为二线治疗。尽管日本已经制定了包括药物治疗在内的指导方针,但亚洲地区ADHD药物的指导方针和使用情况尚不清楚。因此,为了适当地评估ADHD的药物治疗策略,我们调查了亚洲地区儿童ADHD药物治疗指南。我们还审查了马来西亚、新加坡、印度和韩国的指导方针,发现这些指导方针与西方的指导方针不同。
{"title":"Practical clinical guidelines and pharmacological treatment for attention-deficit hyperactivity disorder in Asia.","authors":"Kentaro Kawabe, Fumie Horiuchi, Yu Matsumoto, Saori Inoue, Maya Okazawa, Rie Hosokawa, Kiwamu Nakachi, Junya Soga, Shu-Ichi Ueno","doi":"10.1002/npr2.12381","DOIUrl":"10.1002/npr2.12381","url":null,"abstract":"<p><p>Attention-deficit hyperactivity disorder (ADHD) is characterized by persistent symptoms of inattention, hyperactivity, and impulsivity. Both, stimulant and nonstimulant medications have been approved for the treatment of this disorder. Several Western guidelines recommend the use of prescribed Food and Drug Administration (FDA)-approved medications for ADHD along with parental training in behavior management and behavioral classroom intervention. In 2022, new Japanese guidelines for ADHD were issued, which recommended school environment management and psychosocial treatment as the first-line treatment, with pharmacological treatment added as the second-line treatment. Although Japanese guidelines, including pharmacological treatments, have been established, the guidelines and utilization of ADHD medications across Asian regions are unclear. Therefore, to appropriately evaluate the strategy of pharmacological treatments for ADHD, we investigated Asian regional guidelines for ADHD medication in children. We also reviewed the guidelines in Malaysia, Singapore, India, and the Republic of Korea and found that these guidelines differ from Western guidelines.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10932761/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138499004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of brexpiprazole, aripiprazole, and placebo for Japanese major depressive disorder: A systematic review and network meta-analysis. 比较布雷克哌唑、阿立哌唑和安慰剂对日本重度抑郁障碍的治疗效果:系统综述和网络荟萃分析。
IF 2.5 Q2 Psychology Pub Date : 2024-03-01 Epub Date: 2024-01-14 DOI: 10.1002/npr2.12414
Taro Kishi, Kenji Sakuma, Takeo Saito, Atsuo Nakagawa, Masaki Kato, Nakao Iwata

Aim: This systematic review and frequentist network meta-analysis used random-effects models is conducted to determine whether there are differences in the efficacy, acceptability, tolerability, and safety profiles of brexpiprazole (BRE) and aripiprazole (ARI) for Japanese with major depressive disorder (MDD) who were inadequately responsive to antidepressants.

Methods: Outcome measures were scores on the Montgomery Åsberg Depression Rating Scale (primary), the Clinical Global Impression severity scale, and social functioning scale; the non-response rate; the non-remission rate; all-cause discontinuation; discontinuation due to adverse events (DAE); at least one adverse event (1AE); serious adverse event, akathisia; tremor; weight gain.

Results: A literature search identified three double-blind, randomized, placebo-controlled trials. These comprised one BRE study (with a 1 mg/day [BRE1] and a 2 mg/day [BRE2]) and two ARI studies (with a 3 mg/day arm and a flexible-dose arm[within the dosage range approved in Japan]) (n = 1736). Both BRE and ARI demonstrated better efficacy than the placebo. BRE but not ARI had a higher DAE than the placebo. ARI but not BRE had a higher 1AE than the placebo. BRE and ARI had a higher risk of akathisia and weight gain than the placebo. There were no significant differences between BRE and ARI for any of the outcomes. Although BRE1 had good efficacy, it carried risk of weight gain. Although BRE2 also had efficacy, it carried risks of DAE, akathisia, and weight gain. However, the risk of akathisia in BRE2 was reduced by an initial dose of 0.5 mg/day rather than 1.0 mg/day.

Conclusions: Overall BRE showed similar utility to ARI and a good risk-benefit balance.

目的:本研究采用随机效应模型进行系统综述和频数网络荟萃分析,以确定布雷克哌唑(BRE)和阿立哌唑(ARI)对抗抑郁药反应不足的日本重度抑郁障碍(MDD)患者的疗效、可接受性、耐受性和安全性是否存在差异:结果:结果测量指标包括蒙哥马利-奥斯伯格抑郁评分量表(主要)、临床总体印象严重程度量表和社会功能量表的评分;无反应率;无缓解率;全因停药;因不良事件(DAE)停药;至少一种不良事件(1AE);严重不良事件、运动障碍;震颤;体重增加:文献检索发现了三项双盲、随机、安慰剂对照试验。其中包括一项 BRE 研究(1 毫克/天 [BRE1] 和 2 毫克/天 [BRE2])和两项 ARI 研究(3 毫克/天组和灵活剂量组[在日本批准的剂量范围内])(n = 1736)。BRE 和 ARI 的疗效均优于安慰剂。BRE的DAE高于安慰剂,但ARI的DAE不高于安慰剂。ARI(而非 BRE)的 1AE 高于安慰剂。与安慰剂相比,BRE 和 ARI 出现运动迟缓和体重增加的风险更高。BRE 和 ARI 在任何结果上都没有明显差异。虽然 BRE1 具有良好的疗效,但有体重增加的风险。虽然 BRE2 也有疗效,但它存在 DAE、抽搐和体重增加的风险。然而,BRE2 的初始剂量为 0.5 毫克/天,而不是 1.0 毫克/天,从而降低了运动障碍的风险:总体而言,BRE 的效用与 ARI 相似,且风险-效益平衡良好。
{"title":"Comparison of brexpiprazole, aripiprazole, and placebo for Japanese major depressive disorder: A systematic review and network meta-analysis.","authors":"Taro Kishi, Kenji Sakuma, Takeo Saito, Atsuo Nakagawa, Masaki Kato, Nakao Iwata","doi":"10.1002/npr2.12414","DOIUrl":"10.1002/npr2.12414","url":null,"abstract":"<p><strong>Aim: </strong>This systematic review and frequentist network meta-analysis used random-effects models is conducted to determine whether there are differences in the efficacy, acceptability, tolerability, and safety profiles of brexpiprazole (BRE) and aripiprazole (ARI) for Japanese with major depressive disorder (MDD) who were inadequately responsive to antidepressants.</p><p><strong>Methods: </strong>Outcome measures were scores on the Montgomery Åsberg Depression Rating Scale (primary), the Clinical Global Impression severity scale, and social functioning scale; the non-response rate; the non-remission rate; all-cause discontinuation; discontinuation due to adverse events (DAE); at least one adverse event (1AE); serious adverse event, akathisia; tremor; weight gain.</p><p><strong>Results: </strong>A literature search identified three double-blind, randomized, placebo-controlled trials. These comprised one BRE study (with a 1 mg/day [BRE1] and a 2 mg/day [BRE2]) and two ARI studies (with a 3 mg/day arm and a flexible-dose arm[within the dosage range approved in Japan]) (n = 1736). Both BRE and ARI demonstrated better efficacy than the placebo. BRE but not ARI had a higher DAE than the placebo. ARI but not BRE had a higher 1AE than the placebo. BRE and ARI had a higher risk of akathisia and weight gain than the placebo. There were no significant differences between BRE and ARI for any of the outcomes. Although BRE1 had good efficacy, it carried risk of weight gain. Although BRE2 also had efficacy, it carried risks of DAE, akathisia, and weight gain. However, the risk of akathisia in BRE2 was reduced by an initial dose of 0.5 mg/day rather than 1.0 mg/day.</p><p><strong>Conclusions: </strong>Overall BRE showed similar utility to ARI and a good risk-benefit balance.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10932760/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139466853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gaze measurements during viewing human dialogue scenes in adults with ADHD: Preliminary findings. 成人ADHD患者在观看人类对话场景时的凝视测量:初步发现。
IF 2.5 Q2 Psychology Pub Date : 2024-03-01 Epub Date: 2023-12-04 DOI: 10.1002/npr2.12383
Yuta Nagatsuka, Dan Nakamura, Marie Ota, Gosuke Arai, Yuriko Iwami, Hirohisa Suzuki, Akisa Tomita, Yoichi Hanawa, Wakaho Hayashi, Akira Iwanami

Aim: Eye gaze measurement to human dialogue scenes in adults with attention deficit hyperactivity disorder (ADHD) was investigated. We examined whether eye gaze measurement might be a biological marker of ADHD.

Methods: Twenty-two individuals with ADHD (mean age, 34.5 years) attending the outpatient clinic of Showa University Karasuyama Hospital were included in the study, and 26 healthy individuals (mean age, 32.6 years) with no history of mental disorders were used as the control group. For the participants, intellectual functioning was estimated using the Japanese Adult Reading Test, and mental symptoms were assessed using the Autism Spectrum Quotient and Conner's Adult ADHD Rating Scale. We extracted human dialogue scenes from two classic movies as visual stimuli and recorded the participant's gaze while watching these scenes using Tobii's eye tracker.

Results: For gazing time, repeated measures analysis of variance showed no significant main effect of "group" and no significant interaction effect between "group" and areas of interest "(AOI)." In the normal group, gazing time at the eyes was significantly longer than those at the mouth, body, and background; in the ADHD group, gazing time at the eyes was significantly longer than only that at the background.

Conclusion: Given the different results obtained in the past in ASD, these results suggest that it would be necessary to directly compare the two groups to determine whether the gaze measurement shows significant differences in ASD and ADHD.

目的:探讨成人注意缺陷多动障碍(ADHD)对人类对话场景的注视测量。我们研究了眼睛凝视测量是否可能是ADHD的生物学标记。方法:选取在昭和大学卡拉山医院门诊就诊的22例ADHD患者(平均年龄34.5岁)为研究对象,以26例无精神障碍病史的健康个体(平均年龄32.6岁)为对照组。参与者的智力功能是用日本成人阅读测试来评估的,精神症状是用自闭症谱系商和康纳成人多动症评定量表来评估的。我们从两部经典电影中提取人类对话场景作为视觉刺激,并使用Tobii眼动仪记录参与者在观看这些场景时的目光。结果:对于凝视时间,重复测量方差分析显示“组”的主效应不显著,“组”与“兴趣区域”(AOI)之间无显著交互效应。正常组注视眼睛的时间明显长于注视嘴巴、身体和背景的时间;在ADHD组中,注视眼睛的时间明显长于只注视背景的时间。结论:鉴于过去在ASD中得到的结果不同,这些结果表明,有必要直接比较两组,以确定注视测量在ASD和ADHD中是否存在显著差异。
{"title":"Gaze measurements during viewing human dialogue scenes in adults with ADHD: Preliminary findings.","authors":"Yuta Nagatsuka, Dan Nakamura, Marie Ota, Gosuke Arai, Yuriko Iwami, Hirohisa Suzuki, Akisa Tomita, Yoichi Hanawa, Wakaho Hayashi, Akira Iwanami","doi":"10.1002/npr2.12383","DOIUrl":"10.1002/npr2.12383","url":null,"abstract":"<p><strong>Aim: </strong>Eye gaze measurement to human dialogue scenes in adults with attention deficit hyperactivity disorder (ADHD) was investigated. We examined whether eye gaze measurement might be a biological marker of ADHD.</p><p><strong>Methods: </strong>Twenty-two individuals with ADHD (mean age, 34.5 years) attending the outpatient clinic of Showa University Karasuyama Hospital were included in the study, and 26 healthy individuals (mean age, 32.6 years) with no history of mental disorders were used as the control group. For the participants, intellectual functioning was estimated using the Japanese Adult Reading Test, and mental symptoms were assessed using the Autism Spectrum Quotient and Conner's Adult ADHD Rating Scale. We extracted human dialogue scenes from two classic movies as visual stimuli and recorded the participant's gaze while watching these scenes using Tobii's eye tracker.</p><p><strong>Results: </strong>For gazing time, repeated measures analysis of variance showed no significant main effect of \"group\" and no significant interaction effect between \"group\" and areas of interest \"(AOI).\" In the normal group, gazing time at the eyes was significantly longer than those at the mouth, body, and background; in the ADHD group, gazing time at the eyes was significantly longer than only that at the background.</p><p><strong>Conclusion: </strong>Given the different results obtained in the past in ASD, these results suggest that it would be necessary to directly compare the two groups to determine whether the gaze measurement shows significant differences in ASD and ADHD.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10932770/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138482758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of bilateral repetitive transcranial magnetic stimulation on prospective memory in patients with schizophrenia: A double-blind randomized controlled clinical trial. 双侧重复经颅磁刺激对精神分裂症患者前瞻性记忆的影响:双盲随机对照临床试验。
IF 2.5 Q2 Psychology Pub Date : 2024-03-01 Epub Date: 2023-12-06 DOI: 10.1002/npr2.12397
Fen Xue, Xin-Fu Wang, Fan-Ni Kong, Tian-Lu Yin, Yu-Hong Wang, Li-Da Shi, Xiao-Wen Liu, Hui-Jing Yu, Li-Jun Liu, Ping Zhu, Xiao-Xue Qi, Xue-Jing Xu, Hong-Pu Hu, Su-Xia Li

Aims: To investigate effects of repetitive transcranial magnetic stimulation (rTMS) on the prospective memory (PM) in patients with schizophrenia (SCZ).

Methods: Fifty of 71 patients completed this double-blind placebo-controlled randomized trial and compared with 18 healthy controls' (HCs) PM outcomes. Bilateral 20 Hz rTMS to the dorsolateral prefrontal cortex at 90% RMT administered 5 weekdays for 4 weeks for a total of 20 treatments. The Positive and Negative Symptom Scale (PANSS), the Scale for the Assessment of Negative Symptoms (SANS), and PM test were assessed before and after treatment.

Results: Both Event-based PM (EBPM) and Time-based PM (TBPM) scores at baseline were significantly lower in patients with SCZ than that in HCs. After rTMS treatments, the scores of EBPM in patients with SCZ was significantly improved and had no differences from that in HCs, while the scores of TBPM did not improved. The negative symptom scores on PANSS and the scores of almost all subscales and total scores of SANS were significantly improved in both groups.

Conclusions: Our findings indicated that bilateral high-frequency rTMS treatment can alleviate EBPM but not TBPM in patients with SCZ, as well as improve the negative symptoms.

Significance: Our results provide one therapeutic option for PM in patients with SCZ.

目的:研究重复经颅磁刺激(rTMS)对精神分裂症(SCZ)患者前瞻性记忆(PM)的影响:71名患者中有50人完成了这项双盲安慰剂对照随机试验,并与18名健康对照者(HCs)的前瞻性记忆结果进行了比较。对背外侧前额叶皮层进行双侧 20 赫兹经颅磁刺激,RMT 为 90%,连续 4 周,每周 5 天,共 20 次治疗。对治疗前后的阳性和阴性症状量表(PANSS)、阴性症状评估量表(SANS)以及 PM 测试进行评估:结果:基于事件的 PM(EBPM)和基于时间的 PM(TBPM)基线得分在 SCZ 患者中明显低于 HCs 患者。经颅磁刺激治疗后,SCZ患者的EBPM评分明显改善,与HC患者无差异,而TBPM评分没有改善。两组患者的 PANSS 阴性症状评分以及 SANS 几乎所有分量表的评分和总分均有明显改善:结论:我们的研究结果表明,双侧高频经颅磁刺激治疗可以缓解 SCZ 患者的 EBPM,但不能缓解 TBPM,同时还能改善患者的阴性症状:我们的研究结果为SCZ患者的PM提供了一种治疗方案。
{"title":"Effects of bilateral repetitive transcranial magnetic stimulation on prospective memory in patients with schizophrenia: A double-blind randomized controlled clinical trial.","authors":"Fen Xue, Xin-Fu Wang, Fan-Ni Kong, Tian-Lu Yin, Yu-Hong Wang, Li-Da Shi, Xiao-Wen Liu, Hui-Jing Yu, Li-Jun Liu, Ping Zhu, Xiao-Xue Qi, Xue-Jing Xu, Hong-Pu Hu, Su-Xia Li","doi":"10.1002/npr2.12397","DOIUrl":"10.1002/npr2.12397","url":null,"abstract":"<p><strong>Aims: </strong>To investigate effects of repetitive transcranial magnetic stimulation (rTMS) on the prospective memory (PM) in patients with schizophrenia (SCZ).</p><p><strong>Methods: </strong>Fifty of 71 patients completed this double-blind placebo-controlled randomized trial and compared with 18 healthy controls' (HCs) PM outcomes. Bilateral 20 Hz rTMS to the dorsolateral prefrontal cortex at 90% RMT administered 5 weekdays for 4 weeks for a total of 20 treatments. The Positive and Negative Symptom Scale (PANSS), the Scale for the Assessment of Negative Symptoms (SANS), and PM test were assessed before and after treatment.</p><p><strong>Results: </strong>Both Event-based PM (EBPM) and Time-based PM (TBPM) scores at baseline were significantly lower in patients with SCZ than that in HCs. After rTMS treatments, the scores of EBPM in patients with SCZ was significantly improved and had no differences from that in HCs, while the scores of TBPM did not improved. The negative symptom scores on PANSS and the scores of almost all subscales and total scores of SANS were significantly improved in both groups.</p><p><strong>Conclusions: </strong>Our findings indicated that bilateral high-frequency rTMS treatment can alleviate EBPM but not TBPM in patients with SCZ, as well as improve the negative symptoms.</p><p><strong>Significance: </strong>Our results provide one therapeutic option for PM in patients with SCZ.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10932802/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138488052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A descriptive analysis of spontaneous reports of antipsychotic-induced tardive dyskinesia and other extrapyramidal symptoms in the Japanese Adverse Drug Event Report database. 日本药物不良事件报告数据库中抗精神病药物诱导的迟发性运动障碍和其他锥体外系症状的自发报告的描述性分析。
IF 2.5 Q2 Psychology Pub Date : 2024-03-01 Epub Date: 2023-10-26 DOI: 10.1002/npr2.12385
Yosuke Saga, Chih-Lin Chiang, Akihide Wakamatsu

AimThe aim of this study is to summarize the spontaneous reports of tardive dyskinesia (TD) and extrapyramidal symptoms (EPSs) that occurred in Japan over the past decade. MethodsThe study analyzed TD and EPS cases reported in the Japanese Adverse Drug Event Report database between April 2011 and March 2021. The cases were stratified by the diagnoses of schizophrenia, bipolar disorders, and depressive disorders. ResultsIn total, 800 patients including a total of 171 TD cases and 682 EPS cases were reported in the JADER database across psychiatric diagnosis. The cases were caused by first-generation antipsychotics (FGA, TD: n = 105, EPS: n = 245) and second-generation antipsychotics (SGA, TD: n = 144, EPS: n = 598). The SGA were categorized based on Neuroscience-based Nomenclature (NbN) regarding pharmacological domain and mode of action, which were reported evenly as the offending agents. Among reported treatment and outcome in TD cases (n = 67, 37.6%) and EPS cases (n = 405, 59.3%), the relatively limited number of TD cases were reported as recovered/improved was also limited (n = 32, 47.8%) compared to those of EPS cases (n = 266, 65.7%). Some cases still had residual symptoms or did not recover fully (TD: n = 21, 31.3%, EPS: n = 77, 19.0%). CONCLUSION: Tardive dyskinesia and EPS have been widely reported in Japan over the past decade across psychiatric diagnoses and antipsychotic classes. LIMITATIONS: It is important to acknowledge the presence of reporting bias and the lack of comparators to accurately assess risks. Owing to the nature of spontaneous reporting, the estimation of prevalence is not feasible.

目的总结近十年来日本发生的迟发性运动障碍(TD)和锥体外系症状(EPSs)的自发报告。方法分析2011年4月至2021年3月期间日本药品不良事件报告数据库中报告的TD和EPS病例。根据精神分裂症、双相情感障碍和抑郁障碍的诊断对病例进行分层。结果在JADER数据库中,共报告了800例患者,包括171例TD病例和682例EPS病例。这些病例是由第一代抗精神病药物引起的(FGA,TD:n = 105,每股收益:n = 245)和第二代抗精神病药物(SGA,TD:n = 144,每股收益:n = 598)。SGA是根据基于神经科学的命名法(NbN)关于药理学领域和作用模式进行分类的,这些领域和作用方式被均匀地报告为犯罪因素。在报告的TD病例的治疗和结果中(n = 37.6%)和EPS病例(n = 405例,59.3%),相对有限的TD病例数也有限(n = 32.47.8%)与EPS病例(n = 266例,65.7%)。一些病例仍有残余症状或未完全康复(TD:n = 21,31.3%,每股收益:n = 77.19.0%)。结论:在过去的十年里,日本在精神病诊断和抗精神病药物类别中广泛报道了迟发性运动障碍和EPS。局限性:重要的是要承认存在报告偏差和缺乏准确评估风险的比较标准。由于自发报告的性质,估计流行率是不可行的。
{"title":"A descriptive analysis of spontaneous reports of antipsychotic-induced tardive dyskinesia and other extrapyramidal symptoms in the Japanese Adverse Drug Event Report database.","authors":"Yosuke Saga, Chih-Lin Chiang, Akihide Wakamatsu","doi":"10.1002/npr2.12385","DOIUrl":"10.1002/npr2.12385","url":null,"abstract":"<p><p>AimThe aim of this study is to summarize the spontaneous reports of tardive dyskinesia (TD) and extrapyramidal symptoms (EPSs) that occurred in Japan over the past decade. MethodsThe study analyzed TD and EPS cases reported in the Japanese Adverse Drug Event Report database between April 2011 and March 2021. The cases were stratified by the diagnoses of schizophrenia, bipolar disorders, and depressive disorders. ResultsIn total, 800 patients including a total of 171 TD cases and 682 EPS cases were reported in the JADER database across psychiatric diagnosis. The cases were caused by first-generation antipsychotics (FGA, TD: n = 105, EPS: n = 245) and second-generation antipsychotics (SGA, TD: n = 144, EPS: n = 598). The SGA were categorized based on Neuroscience-based Nomenclature (NbN) regarding pharmacological domain and mode of action, which were reported evenly as the offending agents. Among reported treatment and outcome in TD cases (n = 67, 37.6%) and EPS cases (n = 405, 59.3%), the relatively limited number of TD cases were reported as recovered/improved was also limited (n = 32, 47.8%) compared to those of EPS cases (n = 266, 65.7%). Some cases still had residual symptoms or did not recover fully (TD: n = 21, 31.3%, EPS: n = 77, 19.0%). CONCLUSION: Tardive dyskinesia and EPS have been widely reported in Japan over the past decade across psychiatric diagnoses and antipsychotic classes. LIMITATIONS: It is important to acknowledge the presence of reporting bias and the lack of comparators to accurately assess risks. Owing to the nature of spontaneous reporting, the estimation of prevalence is not feasible.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10932779/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54230323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Neuropsychopharmacology Reports
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1